drugset / Trial / NCT00430040

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

NCT00430040

Phase 4 Terminated 14 enrolled University at Buffalo GlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by suppressing free radicals(charged substances that cause damage to the body ) and inflammation.

Timeline

Start
2007-02
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 80 mg Oral
Subject LISINOPRIL ANHYDROUS Small molecule 20 mg